

UC San Diego

UC San Diego Previously Published Works

Title

Enzymatic chokepoints and synergistic drug targets in the sterol biosynthesis pathway of *Naegleria fowleri*

Permalink

<https://escholarship.org/uc/item/7787k0jr>

Journal

PLOS Pathogens, 14(9)

ISSN

1553-7366

Authors

Zhou, Wenxu

Debnath, Anjan

Jennings, Gareth

et al.

Publication Date

2018

DOI

10.1371/journal.ppat.1007245

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

RESEARCH ARTICLE

Enzymatic chokepoints and synergistic drug targets in the sterol biosynthesis pathway of *Naegleria fowleri*

Wenxu Zhou¹✉, Anjan Debnath²✉, Gareth Jennings², Hye Jee Hahn², Boden H. Vanderloop¹, Minu Chaudhuri³, W. David Nes¹, Larissa M. Podust^{2*}

1 Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, United States of America, **2** Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America, **3** Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, United States of America

✉ These authors contributed equally to this work.

* lpodust@ucsd.edu



OPEN ACCESS

Citation: Zhou W, Debnath A, Jennings G, Hahn HJ, Vanderloop BH, Chaudhuri M, et al. (2018) Enzymatic chokepoints and synergistic drug targets in the sterol biosynthesis pathway of *Naegleria fowleri*. PLoS Pathog 14(9): e1007245. <https://doi.org/10.1371/journal.ppat.1007245>

Editor: William A. Petri, Jr., University of Virginia, UNITED STATES

Received: March 13, 2018

Accepted: July 27, 2018

Published: September 13, 2018

Copyright: © 2018 Zhou et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the University of California San Diego start-up fund to (LMP), the National Institutes of Health grants 1KL2TR001444 (to AD) and R21AI119782 (to WDN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

Naegleria fowleri is a free-living amoeba that can also act as an opportunistic pathogen causing severe brain infection, primary amebic meningoencephalitis (PAM), in humans. The high mortality rate of PAM (exceeding 97%) is attributed to (i) delayed diagnosis, (ii) lack of safe and effective anti-*N. fowleri* drugs, and (iii) difficulty of delivering drugs to the brain. Our work addresses identification of new molecular targets that may link anti-*Naegleria* drug discovery to the existing pharmacopeia of brain-penetrant drugs. Using inhibitors with known mechanism of action as molecular probes, we mapped the sterol biosynthesis pathway of *N. fowleri* by GC-MS analysis of metabolites. Based on this analysis, we chemically validated two enzymes downstream to CYP51, sterol C24-methyltransferase (SMT, ERG6) and sterol Δ^8 - Δ^7 -isomerase (ERG2), as potential therapeutic drug targets in *N. fowleri*. The sterol biosynthetic cascade in *N. fowleri* displayed a mixture of canonical features peculiar to different domains of life: lower eukaryotes, plants and vertebrates. In addition to the cycloartenol→ergosterol biosynthetic route, a route leading to *de novo* cholesterol biosynthesis emerged. Isotopic labeling of the *de novo*-synthesized sterols by feeding *N. gruberi* trophozoites on the U¹³C-glucose-containing growth medium identified an exogenous origin of cholesterol, while 7-dehydrocholesterol (7DHC) had enriched ¹³C-content, suggesting a dual origin of this metabolite both from *de novo* biosynthesis and metabolism of scavenged cholesterol. Sterol homeostasis in *Naegleria* may be orchestrated over the course of its life-cycle by a “switch” between ergosterol and cholesterol biosynthesis. By demonstrating the growth inhibition and synergistic effects of the sterol biosynthesis inhibitors, we validated new, potentially druggable, molecular targets in *N. fowleri*. The similarity of the *Naegleria* sterol Δ^8 - Δ^7 -isomerase to the human non-opioid σ_1 receptor, implicated in human CNS conditions such as addiction, amnesia, pain and depression, provides an incentive to assess structurally diverse small-molecule brain-penetrant drugs targeting the human receptor for anti-*Naegleria* activity.

Competing interests: The authors have declared that no competing interests exist.

Author summary

Sterols are important constituents of cell membranes. In a unicellular organism, such as the human pathogen *N. fowleri*, the cell membrane delineates the physical boundaries of the cell and mediates interactions of the organism with its environment. *N. fowleri* is a free-living amoeba that may infect the human brain causing a fulminant infection called primary amebic meningoencephalitis (PAM). PAM has resulted in death in >97% of reported cases. Understanding the molecular and cellular biology of *N. fowleri* will facilitate the rational development of new therapeutic interventions. Using inhibitors targeting different enzymatic steps in the sterol biosynthesis pathway, we mapped metabolic intermediates and delineated the biosynthetic routes contributing to *N. fowleri* sterol homeostasis. An array of sterol molecules suggests that two different sterol types, ergosterol-like and cholesterol-like sterols, co-exist and may be dynamically regulated in *N. fowleri*. Disruption of sterol biosynthesis by drug candidates was detrimental to *N. fowleri*. Drugs targeting three different enzymatic steps resulted in growth inhibition effect. This effect was amplified when drugs targeting different enzymes were combined. The observed synergistic effect of these drugs lowers the individual drug concentrations required for biological activity including delivering anti-PAM drugs across the blood-brain-barrier.

Introduction

Naegleria fowleri and its non-pathogenic relatives, *Naegleria gruberi* and *Naegleria lovaniensis*, belong to the genus *Naegleria*, class Heterolobosea, which is characterized by a capacity for quick differentiation from an amoeboid to a flagellate form. These amoebae feed mostly on bacteria, but can also act as opportunistic pathogens causing infections of the central nervous system (CNS) of humans and other animals. *N. fowleri* is the only species of the genus known to cause a severe primary amebic meningoencephalitis (PAM) in humans.[1] *Naegleria* occur in three forms—a cyst, a trophozoite (amoeboid), and a biflagellate. The trophozoite is the only feeding and reproductive stage of *Naegleria* spp., as well as the only one found in infected brain tissue[2], while the flagellate form was detected in the cerebrospinal fluid (CSF)[3]. PAM due to *N. fowleri* has a worldwide distribution although it occurs most frequently in tropical areas and during hot summer months.[4]

N. fowleri infection is problematic due to the rapid onset and destructive nature of the disease as well as to the lack of established success in treatment.[5] Until recently, no more than a dozen patients out of ~350 reported PAM cases worldwide have been treated successfully with Amphotericin B (AmpB), either alone or in combination with other drugs.[6–9]. The investigational anti-cancer and anti-leishmaniasis agent miltefosine[10] showed promise, but not all patients who received miltefosine as part of their treatment regimens survived. In 2013, two patients survived out of three treated with miltefosine, but one of the survivors had permanent brain damage.[11] In 2016–2017, two more patients receiving miltefosine survived out of 9 diagnosed with PAM. The lack of a single, proven, evidence-based treatment of PAM with a high probability of cure stimulates a need to further study *Naegleria* biology in order to understand molecular mechanisms maintaining *N. fowleri* homeostasis throughout different developmental stages and dietary conditions.

Sterols are an important class of lipids essential in all eukaryotes. It is assumed that the last eukaryotic common ancestor (LECA) already synthesized sterols.[12] Eukaryotes that lost the ability to synthesize sterols, e.g., insects, worms and most marine invertebrates, have to obtain

them from food. Sterols are involved in both intra- and intercellular signaling and in the organization of membranes. They affect fluidity and permeability of membranes and are major players in the formation of lipid rafts, regions of reduced fluidity formed by the close association of sterols with sphingolipids. [13–15] In unicellular organisms, lipid rafts control endocytosis, vesicle trafficking, motility, and cell signaling and have been shown to regulate adhesion to host cells and control virulence (reviewed in [16]). Ergosterol, a fungal and kinetoplastid sterol, was shown to promote formation of the lipid rafts.[17]

By DNA sequence, *Naegleria* are close to kinetoplastids, however, in contrast to the lanosterol precursor in kinetoplastids,[18] *de novo* biosynthesis of ergosterol in amoebae occurs from cycloartenol, a precursor typical of photosynthetic organisms, i.e., algae and plants.[19–21] Disruption of sterol biosynthesis by small-molecule inhibitors targeting CYP51 is detrimental for *N. fowleri* trophozoites, suggesting that ergosterol biosynthesis is essential for amoeboid survival.[22] Among the enzymes constituting the sterol biosynthetic pathway in eukaryotes, several targets have been studied for the development of therapeutic or agricultural agents. For instance, the HMG-CoA reductase inhibitors, known as statins, are drugs used for lowering serum cholesterol. Farnesyl diphosphate synthase (targeted by bisphosphonates), squalene synthase (aryloxyethyl thiocyanate and quinuclidine derivatives), squalene epoxidase (terbinafine), oxidosqualene cyclase (pyridinium-ion mimetics), sterol 14 α -demethylase (CYP51) (azoles), sterol C24-methyltransferase (SMT) (arylguanidines, azasterols), and sterol Δ^8 – Δ^7 isomerase (ERG2) (morpholines) have been validated as drug targets to treat fungal infections in humans and plants.

In this work, we have assessed the sterol biosynthesis pathway in *N. fowleri* downstream of CYP51 by GC-MS analysis of the metabolic intermediates accumulated in trophozoites in response to the inhibitors with known mechanisms of action (MOA). Using inhibitors as the molecular probes, we chemically validated SMT and ERG2 as essential enzymes in *N. fowleri*. *In vitro* growth inhibition effect were observed for inhibitors of each mechanistic group applied individually. When applied in combination, inhibitors with different MOA produced synergistic effects. The biosynthetic cascade reconstituted in *N. fowleri*, based on the flux of the metabolic intermediates, indicates that the steroidogenic pathway bifurcates into ergosterol and cholesterol arms. The observed sterol profile suggests a possibility of dynamic modulation of sterol homeostasis in *N. fowleri* in response to environmental factors or dietary conditions.

Results and discussion

Sterol biosynthesis enzymes in *Naegleria*

Biosynthetically, sterols are derived from isopentenyl diphosphate (IPP), the precursor of squalene and its downstream cyclized products. The first step leading to sterols adds an oxygen to squalene resulting in squalene epoxide, which is then cyclized in a second step either to lanosterol or to cycloartenol. Enzymes constituting the core sterol biosynthesis pathway in eukaryotes largely exhibit strong conservation in amino acid sequences; however, the pathway architecture and substrate specificity vary.[23] Steroidogenesis in the non-pathogenic environmental *Naegleria* species, *N. gruberi* and *N. lovaniences*, was assessed in the pre-genomic era. [20] Following up on results from earlier studies[22], we have now interrogated the sterol biosynthesis pathway in *N. fowleri*. *Naegleria* steroidogenic enzymes were identified by sequence homology to the yeast, human and plant orthologues. They are characterized by high intra-genus sequence similarities and lower similarity to the human counterparts, the latter ranging from 32 to 56% for homologous enzymes (S1 Table). The Δ^{24} -reduction and Δ^8 – Δ^7 -isomerization steps are performed by non-homologous enzyme pairs (<20% sequence identity), ERG4 and ERG2 in fungi, DHCR24/DWF1 and EBP/HYD1 in vertebrates/land plants

respectively. The *Naegleria* enzymes are homologous to fungal orthologues, suggesting that both can be exploited therapeutically.

The 3-keto-steroid reductase and C22-desaturase could not be identified in *Naegleria* by homology with yeast, human or plant counterparts. The *Naegleria* 3-keto-steroid reductase that catalyzes the last of the three steps required to remove two C-4 methyl groups may be homologous to yet unknown C-3 ketoreductase in land plants.[12] A protein with similarity to CYP710A, equivalent to 22-desaturase in higher plants, is present in *N. gruberi* (XP_002678320.1), but its primary sequence is closer to that of CYP51. In animals, lack of 22-desaturase is a typical feature. The 24-alkylation performed by ERG6 is present in *Naegleria* but absent in animals.

The sterol metabolic network in *N. fowleri*

We used sterol biosynthesis inhibitors with different MOA to (i) interrogate the flux of sterol intermediates, (ii) access the physiological requirement for specific sterols and (iii) identify enzymatic chokepoints essential to trophozoite growth. The sterol biosynthetic cascade, reconstituted in *N. fowleri* based on the flux of the metabolic intermediates, is consistent with the earlier data [20, 22] that sterol biosynthesis in *Naegleria* proceeds from cycloartenol (22) via 31-norlanosterol (14) to ergosterol (7) (Fig 1). Cholesterol (1), 7-dehydrocholesterol (7DHC) (3), ergosterol (7) and its biosynthetic precursor ergosta-5,7-dienol (10) are the most abundant sterols dominating lipid extracts of the non-inhibited *N. fowleri* and *N. gruberi* trophozoites, whereas 4-monomethylsterols, 4,4-dimethyl intermediates and 14 α -methylsterols are sparsely represented (Table 1).

Given structural similarity of sterol substrates, enzyme specificity is controlled kinetically rather than thermodynamically. Disruption of specific steps gives rise to the uncommon intermediates that are enzymatically converted to the end-products not operational in the wild-type organism. As reported previously,[22] upon treatment of *N. fowleri* with posaconazole, the cumulative content of the 14 α -methylsterols, including 12, 14, 16, 19, 20, 21 and 22, increased from 6.5% to 49.1%, with the major intermediate being 31-norlanosterol (14) followed by its C24-C25 hydrogenated product, 4,14-dimethylcholest-8-enol (12). Posaconazole data reported elsewhere[22] are included in Table 1 as a comparative companion in the context of the whole pathway. Given the unchanged content of 4,4-dimethylsterols in the CYP51 inhibitor-exposed samples, removal of the 4 β -methyl group is unaffected by the blocking of CYP51 activity and likely occurs prior to the C-14 demethylation; removal of the 4 α -methyl group occurs downstream to CYP51. The C-4 demethylation in two nonconsecutive steps is a feature of land plants.[12] In this work, by using molecular probes with the corresponding MOA, we mapped enzymatic steps downstream of CYP51, including sterol C8 \rightarrow C7-double bond isomerization, catalyzed by ERG2, and sterol C24-methylation, catalyzed by SMT (ERG6).

In an ERG2 inhibitor AY9944-treated *N. fowleri*, the 4 α -methylcholesta-8,24-dienol (15) content increased from zero to 19.1% suggesting that the 4 α -demethylation follows the Δ^8 - Δ^7 -isomerization and preferably occurs on 4 α -methylcholesta-7,24-dienol (17). The treatment of *N. fowleri* with another ERG2 inhibitor, tamoxifen, a non-steroidal estrogen receptor modulator, also resulted in an increase of the ergosta-5,7-dienol (10) content from 21.3% to 43.5% (Fig 1, Table 1), suggesting an inhibition of 22-desaturation performed by a yet unknown *Naegleria* enzyme.

Exposure of *N. fowleri* to the SMT inhibitors 24,25-epiminolanosterol (epiminolanosterol), abafungin and 25-azacycloartenol (25-Aza), led to high accumulation of cholesta-5,7,24-trienol (6) ($\geq 30\%$ of total sterols), an intermediate undetectable in the wild-type or




Fig 1. Sterol metabolic network in *N. fowleri*. The pathway is reconstituted based on the metabolites observed in the untreated *N. fowleri* (shown in bold) and treated with the CYP51 (shown in green), SMT (in blue) and ERG2 (in dark red) inhibitors. Metabolites not observed in the wild-type *N. fowleri* are depicted in thin lines. The cholesterol arm of the pathway is highlighted by the yellow-green background, the ergosterol arm is highlighted by the blue background. Enclosed in frame are potential SMT substrates. Enzymes interrogated in these studies are labeled in colors corresponding to the accumulating metabolites. Numbering of atoms in sterol molecule is adapted from Nes and Venkatramesh, 1994.[41] Sterol labelling is as in Table 1. ERG enzyme nomenclature is according to the convention for *S. cerevisiae*.

<https://doi.org/10.1371/journal.ppat.1007245.g001>

posaconazole-inhibited *N. fowleri* (Table 1, Fig 2). This finding made three intermediates, 5, 8 and 6, potential candidates for endogenous SMT substrates in *N. fowleri*. All three contain a $\Delta^{24(25)}$ olefin group that allows C-methylation with formation of the transient 24-methylene intermediate that ultimately is converted to the ergosterol-like physiological end-products (Fig 1).[24, 25] In the SMT-inhibited *N. fowleri*, the end-products 9 and 2, not operational in the wild-type *N. fowleri*, were also formed. Accumulation of cholesta-5,7,22,24-tetraenol (9) and cholesta-5,7,24-trienol (2), the end products representing a dysfunctional carbon flux, was previously reported in yeast carrying an ERG6 mutant defective in SMT activity.[26]

Functional analysis of *Naegleria* sterol C24-methyltransferase (SMT)

To identify what configuration of the double-bond(s) in the sterol B-ring favors *Naegleria* SMT catalysis, the studies using recombinant enzyme and individually isolated sterol

Table 1. Sterol flux in *N. fowleri*.

| ## | Metabolites ^a | RRT ^b | Non-inhibited | | CYP51 | SMT | | | Sterol $\Delta^8-\Delta^7$ -isomerase | |
|----|---|------------------|---------------|-----------------|---------------------------|-------------------|-------------|-------------|---------------------------------------|-------------|
| | | | NG | NF ^c | Posaconazole ^c | Epiminolanosterol | Abafungin | 25-Aza | Tamoxifen | AY9944 |
| 1 | Cholesterol | 1 | 7.6 | 25.6 | 26.0 | 15.6 | 2.0 | 12.7 | 3.0 | 9.5 |
| | 4-Desmethylsterols (w/o cholesterol) | | 77.6 | 62.9 | 23.8 | 61.9 | 88.8 | 74.5 | 71.9 | 54.6 |
| 2 | Cholesta-5,7,22-trienol | 1 | | | | 3.3 | 4.3 | 2.9 | | |
| 3 | 7-Dehydrocholesterol (7DHC) | 1.04 | 10.8 | 12.5 | 3.9 | 9.9 | 13.8 | 12.9 | 4.1 | 7.5 |
| 4 | Lathosterol | 1.06 | | 0.8 | | | 0.2 | | | |
| 5 | Zymosterol | 1.07 | | 0.4 | | 0.1 | | 0.1 | | |
| 6 | Cholesta-5,7,24-trienol | 1.11 | | | | 30.8 | 30.0 | 38.8 | | |
| 7 | Ergosterol | 1.11 | 35.5 | 26.7 | 14.2 | 7.7 | 20.7 | 8.8 | 24.3 | 22.8 |
| 8 | Cholesta-7,24-dienol | 1.12 | | | | 1.6 | 5.5 | 2.8 | | |
| 9 | Cholesta-5,7,22,24-Tetraenol | 1.20 | | | | 6.9 | 8.6 | 5.3 | | |
| 10 | Ergosta-5,7-dienol | 1.21 | 31.1 | 21.3 | 5.7 | 1.6 | 5.7 | 2.9 | 43.5 | 24.3 |
| 11 | Ergost-7-enol | 1.22 | 0.2 | 1.2 | | | | | | |
| | 4-Monomethylsterols | | 2.1 | 6.8 | 48.5 | 20.8 | 8.0 | 10.5 | 13.9 | 29.7 |
| 12 | 4 α ,14 α -Dimethylcholest-8-enol | 1.08 | 0.1 | 1.1 | 15.5 | | | | | |
| 13 | 4 α -Methylcholest-8-enol | 1.11 | | 3.5 | 0.4 | 7.6 | 7.2 | 2.6 | 10.4 | 5.7 |
| 14 | 31-Norlanosterol | 1.14 | 2.0 | 2.2 | 29.7 | 0.5 | | 1.4 | | |
| 15 | 4 α -Methylcholesta-8,24-dienol | 1.18 | | | | 9.1 | 0.4 | 1.5 | 3.5 | 19.1 |
| 16 | Δ^7 -31-norlanosterol | 1.24 | | | 2.9 | | | | | |
| 17 | 4 α -Methylcholesta-7,24-dienol | 1.26 | | | | 3.6 | 0.4 | 5.0 | | 2.9 |
| 18 | 4 α -Methylergosta-8,24(28)dienol | 1.31 | | | | | | | | 2.0 |
| | 4,4-Dimethylsterols | | 9.6 | 3.3 | 1.0 | 0.9 | 0.6 | 0.9 | 2.3 | 0.8 |
| 19 | Lanostanol | 1.30 | 0.5 | 0.2 | 0.2 | 0.4 | 0.5 | | | |
| 20 | Cycloartanol | 1.32 | 6.9 | 1.1 | | | | | | |
| 21 | Parkeol | 1.40 | 0.3 | | 0.1 | 0.1 | | 0.3 | | |
| 22 | Cycloartenol | 1.41 | 1.9 | 2.0 | 0.7 | 0.4 | 0.1 | 0.6 | 2.3 | 0.8 |
| | Other sterols | | 3.1 | 1.4 | 0.7 | 0.8 | 0.6 | 1.4 | 8.9 | 5.4 |

^aAll listed sterol structures are shown in Fig 1. The metabolites were quantified based on the total ion current peak areas of each sterol. NF–*N. fowleri*, NG–*N. gruberi*

^bRelative retention time compared to cholesterol

^cPreviously published data[22] used here as a comparative companion in the context of the whole pathway.

<https://doi.org/10.1371/journal.ppat.1007245.t001>

intermediates were conducted. In the *N. gruberi* genome, two candidate genes encoding SMT (77.6% sequence identity) were identified (S1 Table), which resemble those of higher plants in primary sequence (~50% identity). Higher plants have two SMT enzymes that use different substrates to give either C24-methylated or C24-ethylated phytosterols. *N. fowleri* has a single gene encoding SMT; no 24-ethylated sterols were detected in the lipid extracts of any *Naegleria* species. *N. gruberi* SMT (XP_002680047.1) sharing highest sequence identity (86%) with the *N. fowleri* counterpart, has been expressed in *Escherichia coli* and recombinant protein was characterized for substrate specificity. From the *in vitro* reconstitution of the SMT catalytic activity, among thirteen sterols tested, 5 (zymosterol) and 6 (cholesta-5,7,24-trienol) were equipotent as SMT substrates (set at 100%), while 8 (cholesta-7,24-dienol) showed 67.2% conversion (Table 2).

An origin of cholesterol in *Naegleria*

Remarkably, in addition to the ergosterol ‘arm’ (highlighted blue in Fig 1), a cholesterol arm, characterized by reactions 8→4→3→1 (highlighted orange in Fig 1), emerged in the




Fig 2. Lipid analysis by GC-MS. Gas chromatography of the total sterol fractions derived from *N. fowleri* trophozoites treated with (A) 0.5% DMSO, (B) 0.2 μM posaconazole, (C) 5.4 μM epiminolanosterol, and (D) 5.6 μM AY9944. Peaks are labeled with numbers corresponding to metabolites listed in Table 1. Insert in (C) shows deconvolution of the major peak resulting from an overlap of three different sterols: 6, m/z = 349; 7, m/z = 363 and 13, m/z = 400. The color scheme is the same as in Fig 1: CYP51 inhibitor (shown in green), SMT inhibitor (in blue) and ERG2 inhibitor (in dark red).

<https://doi.org/10.1371/journal.ppat.1007245.g002>

metabolic flux studies. Together with the high cholesterol content, this observation raised a question about the origin of cholesterol: *de novo* biosynthesis or scavenging from the growth medium. To answer this question, we have conducted the ¹³C-labeling studies in *N. gruberi*

Table 2. Conversion of different sterols by *N. gruberi* SMT.

| Substrates | Relative Activities (%) |
|-----------------------------|-------------------------|
| fecosterol | 0.0 |
| 24-methylenelophenol | 0.0 |
| zymosterol (5) | 100.0 |
| cholesta-5,7,24-trienol (6) | 100.0 |
| cholesta-7,24-dienol (8) | 67.2 |
| 14α-methylzymosterol | 29.0 |
| desmosterol | 17.10 |
| 4α-methylzymosterol | 9.4 |
| 31-norlanosterol (14) | 2.7 |
| cycloartenol (22) | 0.0 |
| 24-methylenecycloartenol | 0.0 |
| lanosterol (19) | 0.0 |
| obtusifolol | 0.0 |

<https://doi.org/10.1371/journal.ppat.1007245.t002>

Table 3. Isotopic enrichment of *N. gruberi* sterols incubated with 50 mM U-¹³C-glucose.

| Sterols | Molecular Formula | ¹³ C-content in normal medium (%) | ¹³ C-content in U ¹³ C-glucose medium (%) |
|---------------------|-----------------------------------|--|---|
| Cholesterol | C ₂₇ H ₄₆ O | 1.07 | 1.06 |
| Cholesta-5,7-dienol | C ₂₇ H ₄₄ O | 1.11 | 2.46 |
| Ergosterol | C ₂₈ H ₄₄ O | 1.06 | 4.02 |
| Erosta-5,7-dienol | C ₂₈ H ₄₆ O | 1.11 | 4.03 |
| Cycloartenol | C ₃₀ H ₅₀ O | 1.15 | 4.15 |

<https://doi.org/10.1371/journal.ppat.1007245.t003>

grown in the ATCC1034 medium supplemented with U-¹³C glucose to the final concentration of 5% (w/v). Incorporation of the ¹³C-carbon was monitored by GC/MS; a percent of the ¹³C enrichment for each sterol was calculated from the isotopic distribution of the molecular mass using IsoCor software.[27] As expected, cycloartenol, ergosta-5,7-dienol and ergosterol made by amoeba biosynthetically, had the highest ¹³C-isotope content (Table 3). At the same time, cholesterol was unlabeled, proving its exogenous origin in cultured *N. gruberi* trophozoites. Remarkably, ¹³C-isotope content in 7-dehydrocholesterol (3) fall between the ergosterol and cholesterol values, suggesting dual origin of this intermediate in both the *de novo* biosynthesis and via a reverse reaction catalyzed in other species by cholesterol C-7 desaturase. Cholesterol 7-desaturase is a critical enzyme in insects and nematodes involved in the synthesis of steroid hormones (DAF-36).[28] These lineages lack sterol biosynthesis capacity and rely solely on cholesterol uptake from the diet. Both *N. fowleri* and *N. gruberi* genomes encode a putative DAF-36-like protein (S1 Table).

The dual origin of 7DHC extends the cholesterol arm all the way from 8→4→3 (Fig 1). The last 3→1 step separating *N. fowleri* from making cholesterol *de novo*, the reduction of the C7-C8-double bond in 7-dehydrocholesterol usually performed by Δ⁷-dehydrocholesterol reductase, remains unobserved. Candidates for this enzymatic role are present in both *N. fowleri* and *N. gruberi* genomes (S1 Table). A possibility of the pathway bifurcation downstream of 8 suggests a “switch” between the C24-methylation and Δ²⁴-reduction steps (Fig 1) committing *Naegleria* to either ergosterol or cholesterol biosynthesis, respectively. We hypothesize that the switch may be used to maintain dynamic sterol homeostasis over the course of the *N. fowleri* life-cycle.

Anti-proliferative and synergistic effects of sterol biosynthesis inhibitors

The growth inhibition of free-living amoebae by the sterol biosynthesis inhibitors has been reported previously. Thus, the effect of the agricultural systemic fungicides, tridemorph and fenpropimorph, which target both sterol Δ⁸-Δ⁷-isomerase and Δ¹⁴-reductase,[29] has been reported in *Acanthamoeba polyphaga*, *N. lovaniensis* and *N. gruberi* in the mid 80's.[20, 21] More recently, growth inhibition of *Acanthamoeba castellanii* and *A. polyphaga* was demonstrated by the pharmaceutical sterol biosynthesis inhibitors, itraconazole and voriconazole, targeting CYP51.[30] Finally, posaconazole and itraconazole were found superior to AmpB, a cornerstone of PAM therapy and a standard of care for CNS infections caused by molds, against *N. fowleri* trophozoites *in vitro*.[22] In this work, we demonstrated that blocking enzymatic steps downstream of CYP51, leads to a decline of ergosterol and/or accumulation of the end-products and metabolic intermediates incompatible with *N. fowleri* survival *in vitro*. The anti-proliferative effects of compounds were assessed using methods previously described.[7, 22] The EC₅₀ values of the individual inhibitors deduced from the dose-response curves (Fig 3) are summarized in Table 4. For drug compatibility in combination experiments, all compound stocks were prepared in DMSO, which negatively affected the isavuconazole and




Fig 3. Dose-response growth inhibition of *N. fowleri* trophozoites. Dose-response curves are shown for (A) SMT inhibitors: abafungin, 25-azacycloartenol and 24,25-epiminolanosterol, (B) ERG2 inhibitors: tamoxifen and AY9944, (C) CYP51 inhibitor isavuconazole.

<https://doi.org/10.1371/journal.ppat.1007245.g003>

posaconazole EC₅₀ values compared to previously determined for the SBE-β-CD-solubilized drug.[22] The *in vitro* potency of all tested sterol biosynthesis inhibitors exceeded that of miltefosine (EC₅₀ of 54.5 μM), an investigational drug currently recommended by the U.S. Centers for Disease Control and Prevention for the treatment of PAM.

Blocking two essential enzymes in the ergosterol pathway is more detrimental for unicellular organisms than inhibiting one.[31] This synergistic effect is due to more efficient depletion of an essential end product(s) and/or redirection of substrate flow to produce intermediates and end-products harmful for key steroidogenic enzymes or membrane structures. In this

Table 4. Targeting *N. fowleri* with inhibitors of known MOA.

| Inhibitors | EC ₅₀ , ^a M <i>N. fowleri</i> |
|--|--|
| CYP51 (ERG11) | |
| Posaconazole ^a | ≤0.01[22] |
| Posaconazole | 0.2±0.08 |
| Isavuconazole ^a | 0.1[22] |
| Isavuconazole | 1.6±0.03 |
| SMT (ERG6) | |
| Abafungin | 3.1±0.02 |
| Epiminolanosterol | 5.4±0.03 |
| 25-Azacycloartenol | 14.3±0.04 |
| Sterol Δ⁸-Δ⁷ isomerase (ERG2) | |
| Tamoxifen | 5.8±0.04 |
| AY9944 | 5.6±0.03 |
| Human σ₁ receptor | |
| Fluoxetine (Prozac) | 31.8±0.01 |
| Fluvoxamine (Luvox) | 42% at 50 μM |
| Citalopram (Celexa) | 21% at 50 μM |
| Dextromethorphan (DXM) | 20% at 50μM |
| Standards of care | |
| AmpB ^a | 0.10±0.01[22] |
| Miltefosine | 54.4±0.01[22] |

^asolubilised in SBE-β-CD

<https://doi.org/10.1371/journal.ppat.1007245.t004>

work, we have demonstrated synergy between the CYP51 (isavuconazole), SMT (epiminolanosterol) and sterol ERG2 (tamoxifen) inhibitors paired in three different combinations as specified in Fig 4. Using classical isobolograms, combination indices (CI) and dose reduction indices (DRI) were calculated from the experimental data (Fig 4A, 4B and 4C) as described by Chou and Talalay (S2 Table). [32, 33] The isobolograms indicate synergy for all three drug pairs in achieving 95% of *N. fowleri* growth inhibition with 2- to 19-fold dose reduction for isavuconazole and 1- to 19-fold dose reduction for tamoxifen (Fig 4D); 3- to 109-fold dose reduction for epiminolanosterol and 2- to 16-fold dose reduction for tamoxifen (Fig 4E); and finally, the highest synergy with 4- to 265-fold dose reduction for isavuconazole and 13- to 132-fold dose reduction for epiminolanosterol is indicated for the isavuconazole-epiminolanosterol pair (Fig 4F).

The drug combinations with the highest predicted synergy were analyzed microscopically for their effect on *N. fowleri* growth and morphology (Fig 5). The isavuconazole-epiminolanosterol pair, combined at concentrations of 0.08 μM and 0.7 μM, respectively, (CI = 0.07) (Fig 5A), the isavuconazole-tamoxifen pair, combined at 1.9 μM equimolar concentrations (CI = 0.36) (Fig 5B), and epiminolanosterol and tamoxifen pair, combined at 2 μM equimolar concentrations (CI = 0.38) (Fig 5C), completely inhibited the growth and led to the changed morphology and death of the majority of *N. fowleri* cells in 48 h of drug exposure, whereas DMSO-treated control cells grew and appeared normal (Fig 5D).

New therapeutic targets and blood-brain permeability of drugs

Drug ‘repurposing’ is a relevant and cost effective strategy for utilizing approved drugs for the treatment of rare diseases. The requirement of brain penetrance narrows down the pool of the




Fig 4. Growth inhibition of *N. fowleri* as a function of drug combinations. Heat maps show growth inhibition of *N. fowleri* by drug combinations: tamoxifen and isavuconazole (A), epiminlanosterol and tamoxifen (B), and epiminlanosterol and isavuconazole (C). Corresponding isobolograms (D, E, F) show the mean values of dose reduction index (DRI) plotted against calculated inhibitor doses required to achieve 95% growth inhibition. Standard deviations for each parameter mean value are shown in S2 Table.

<https://doi.org/10.1371/journal.ppat.1007245.g004>




Fig 5. Synergistic effect of drugs at low concentrations. The phase contrast microscope images show *N. fowleri* trophozoites treated for 48 hours with (A) 0.08 μM of isavuconazole and 0.7 μM of epiminolanosterol, (B) 1.9 μM equimolar concentrations of isavuconazole and tamoxifen, (C) 2 μM equimolar concentrations of epiminolanosterol and tamoxifen, and (D) 0.5% DMSO, which served as a negative control. The inhibitor-treated *N. fowleri* cells visible in the microscope field are rounded, much smaller in size and not viable, whereas DMSO-treated cells are irregularly shaped with visible cytoplasm. Magnification, $\times 20$.

<https://doi.org/10.1371/journal.ppat.1007245.g005>

FDA-approved candidates for the treatment of PAM. Only a few diseases of the brain like depression, affective disorders, chronic pain, and epilepsy respond to small-molecule therapy. The reason for the paucity of small-molecule drugs is that 98% of them do not cross the blood-brain barrier (BBB).[34, 35] Validation of sterol $\Delta^8-\Delta^7$ -isomerase (ERG2) as a new potential molecular drug target in *N. fowleri* provides a link to structurally diverse brain-penetrant small-molecule drugs targeting human non-opioid σ_1 receptor sharing 30% sequence identity and 60% sequence homology to the catalytic domain of the *N. fowleri* sterol $\Delta^8-\Delta^7$ -isomerase (Fig 6). The non-opioid σ_1 receptor is implicated in human CNS conditions such as addiction, amnesia, pain and depression.[36]

We have tested four non-selective serotonin reuptake inhibitors (SSRIs) and σ_1 receptor agonists with reported affinity to human σ_1 receptors, fluvoxamine (Luvox), fluoxetine (Prozac), citalopram (Celexa) and dextromethorphan (DXM), [37, 38] for growth inhibition against *N. fowleri*. All four drugs demonstrated effect at the highest tested concentration




Fig 6. Sequence alignments between the catalytic domain of sterol Δ^8 - Δ^7 -isomerase (ERG2) and a ligand binding site of non-opioid σ_1 receptor (SGMR1) demonstrate high sequence similarity. Accession numbers in UniProt or AmoebaDB are provided for each sequence. Numbering is according to the *Dictyostelium discoideum* ERG2 sequence.

<https://doi.org/10.1371/journal.ppat.1007245.g006>

(50 μ M). Fluoxetine, the well-known antidepressant, was the most potent in this group (Table 4). Potency of fluoxetine (EC₅₀ of 32 μ M) exceeded that of miltefosine (54 μ M). Other structurally diverse brain-penetrant small-molecule drugs targeting this human receptor will now be screened for anti-*Naegleria* activity to identify candidates for animal model studies.

Summary

The sterol biosynthetic pathway in *N. fowleri* displays a mixture of canonic features peculiar to different domains of life: lower eukaryotes, land plants, invertebrates and vertebrates. In addition to the cycloartenol→ergosterol biosynthetic route, our data suggest a route leading to *de novo* cholesterol biosynthesis with a single, yet to be experimentally observed, enzymatic step separating *N. fowleri* from making cholesterol *de novo*. *N. fowleri* also utilizes cholesterol obtained from diet by converting it into 7-dehydrocholesterol, a feature typical to the eukaryote lineages (e.g., insects, worms and marine invertebrates) that lost the ability to produce sterols from squalene. Hypothetically, a “switch” between ergosterol and cholesterol sterol types may occur in *Naegleria*, e.g., during encystation/excystation, to sustain environmental challenges by forming a viable cyst. By demonstrating the amoebicidal effect of the sterol biosynthesis inhibitors with different MOA, we validated multiple, potentially druggable, molecular targets in *N. fowleri*, linking the anti-*Naegleria* drug discovery to the existing small-molecule drugs targeting other human diseases. Synergy between alternative drug-targets is of interest for the treatment of PAM, as lower drug concentrations are required to achieve the biologic effect. Reducing therapeutic concentrations may, in part, alleviate the limitation imposed by the need of delivering anti-PAM drugs across the blood-brain-barrier.

Materials and methods

Ethics statement

Research performed at UC San Diego was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to the principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011. The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Animal research was conducted under approved protocol S14187 from the Institutional Animal Care and Use Committee, University of California, San Diego.

Euthanasia was accomplished by CO₂ inhalation or by sodium pentobarbital overdose (60 mg/kg), followed by cervical dislocation. These methods of euthanasia have been selected because they cause minimal pain and distress to animals, are relatively quick, and do not adversely impact interpretation of the results of studies. All methods are in accord with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association.

Compounds

The inhibitors tested were purchased from commercial vendors except epiminolasosterol and 25-azacycloartenol which were synthesized in Dr. Nes' laboratory; the structure of the sterol was authenticated by both the GC-MS and NMR methods. AY9944 and abafungin were from Santa Cruz Biotechnology (SC-202965 and SC-474844); tamoxifen was from Sigma (T5648), isavuconazole was from StruChem (SC-98350), fluvoxamine (J90043), fluoxetine (C845), citalopram (K750) and dextromethorphan (X3585) were from AK Scientific.

N. fowleri strain maintenance

The *N. fowleri* KUL strain used in these studies was acquired from ATCC in 2015; aliquoted stock is maintained deep frozen in liquid nitrogen. *N. fowleri* amoebae maintained axenically (in culture) are weakly virulent. To maintain highly virulent status, *N. fowleri* strain is passaged every six months in mouse brain. For that, four week-old male Balb/c mice are inoculated by intranasal instillation of 10 μ l of 3×10^4 *N. fowleri* trophozoites axenically cultured at 37°C in Nelson's medium supplemented with 10% fetal bovine serum, resulting in 100% animal mortality at day 7. Female mice are less susceptible to *N. fowleri* infection, therefore only male mice are used in this model. At the time point when clinical signs of infection are apparent, the mice are sacrificed and the brains are harvested to propagate *N. fowleri* axenically for the next few months. The animals and tissues infected with *N. fowleri* are handled in the certified Biosafety Level-2 (BSL-2) environment according to the UCSD Institutional Animal Care and Use Committee guidelines and approved animal protocol. Safety glasses, gloves, mask, disposal gowns, shoe covers and head cover are worn. *N. fowleri* strain is handled in a biosafety cabinet mounted in the BSL-2 environment.

N. fowleri growth inhibition assay

To determine EC₅₀ values, test compounds were tested for dose-response against *N. fowleri* trophozoites axenically cultured in Nelson's medium supplemented with 10% fetal bovine serum at 37°C; [39] all the experiments were performed in triplicate using trophozoites harvested during the logarithmic phase of growth. [40] Drug concentration ranges of 0.4–50 μ M and 0.008–25 μ M were generated by transferring 0.5 μ l of serially diluted compounds to a corresponding well of the 96-well plate followed by addition of 99.5 μ l of *N. fowleri* trophozoites (10,000 amoebae). Assay plates were incubated for 48 h and cell viability was determined by the CellTiter-Glo Luminescent Cell Viability Assay. [7, 40] The experiments using trophozoites were conducted in a biosafety cabinet following the BSL-2 procedures as specified in the UCSD Biosafety Practices Guidelines.

GC-MS analysis of the *Naegleria* sterols

Twenty or fifty million *N. gruberi* or *N. fowleri* trophozoites per sample were exposed for 24 h to 0.5% DMSO or an inhibitor at EC₅₀ concentration prior to lipid extraction. Sterols were analyzed by the use of GC-MS, wherein the lipids extracted from cells grown in the presence of non-lethal concentrations of inhibitors are separated by gas chromatography and

subsequently analyzed by mass-spectrometry, as previously described.[22] The sterol identities were assigned based on relative chromatographic behavior, the characteristic molecular masses and electron ionization (EI) fragmentation patterns of free sterols (Fig 2). The sterols were quantified based on the total ion current peak areas of each sterol.

Catalytic activity of recombinant SMT

The cDNA coding sequence for XP_002680047 was retrieved from NCBI database and the gene was synthesized by Eurofin MWG (Huntsville, AL). The gene was cloned into the PQE30 plasmid (Qiagen) and expressed in *E. coli* M15 strain. Briefly, the M15 *E. coli* cells harboring expression vector were grown at 37°C in Luria broth (LB) containing ampicillin and kanamycin until OD₆₀₀ reached 0.6. The gene expression was induced by 1.0 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 6 hours. The cells were collected by centrifugation and homogenized in 20 mM phosphate buffer in 5% (v/v) glycerol at pH 7.5. After removal of the cell debris by centrifugation at 100,000×g, the soluble fraction was analyzed by Bradford assay to determine the total protein concentration.

To assess the catalytic activity of SMT, thirteen different sterol substrates specified in Table 2 were used. Enzymatic assays were carried out using crude SMT preparation in 9-ml test tubes containing a total of 600 μl assay volume at 35°C for 4 hours. The assay mixture contained 100 μM sterol emulsified in 12 μl Tween 80 (1.2g/L) and 1.2 mg of total protein. The reaction was initiated by the addition of 200 μM of S-adenosyl methionine. The reactions were terminated with 1 ml of methanolic KOH. Sterols were extracted with hexane (3 x 1 ml) and dried under an N₂ stream. The extracted sterols were separated by GC/MS and the substrate conversion rate (R) was calculated from the GC peak areas for the substrate (S) and the product (P) peaks according to the following equation: $R = 1 - P/(S+P)$. The conversion rates were normalized to the activity of the two best substrates, 5 and 6, which was considered as 100%.

Validation of the inhibitors for growth inhibition activity

Compounds were tested against *N. fowleri* KUL trophozoites axenically cultured in Nelson's medium supplemented with 10% fetal bovine serum at 37°C.[22] All the experiments were performed using trophozoites harvested during the logarithmic phase of growth. Screening was performed in triplicate by using an ATP bioluminescence-based assay[40] as previously described.[22] The experiments using trophozoites were conducted in a biosafety cabinet following the BSL2 procedures as specified in the UCSD Biosafety Practices Guidelines.

Determination of FIC indices and isobologram construction

To determine if the combinations between the inhibitors are synergistic, additive, or antagonistic against *N. fowleri* trophozoites, classical isobolograms were used, and combination indices (CI) were calculated as described by Chou and Talalay.[32, 33] Briefly, compounds (epiminolanosterol/tamoxifen, isavuconazole/epiminolanosterol, isavuconazole/tamoxifen) were combined at different micromolar ratios (1:1, 1:2, 1:4, 1:8, 1:16, 2:1, 4:1, 8:1 and 16:1) at each drug concentrations ranging from 50 μM to 0.4 μM (Fig 4). Effect for drug pairs was assessed in triplicate in 96-well format with each drug being serially diluted either horizontally or vertically. Growth inhibition was assessed after 48 h using an ATP bioluminescence-based assay.[22]. The results were analyzed using CompuSyn software[32] that calculated combination indices serving as a quantitative measure for drug synergy (CI<1), additivity (CI = 1), or antagonism (CI>1). The dose reduction index (DRI), a fold of dose reduction that allows drug combination to achieve the same degree of inhibition as a dose of the drug used as a single agent, was also calculated by the CompuSyn software.

The predicted synergistic effect of drugs was experimentally tested in a 96-well clear bottom plate. *N. fowleri* trophozoites (1×10^4) were treated with pairs of compounds (isavuconazole/epiminolanosterol, isavuconazole/tamoxifen and epiminolanosterol/tamoxifen) mixed at concentrations that provided the highest CI at 48 h. Cells treated with 0.5% DMSO were used as control. After 48 hours, wells were visually inspected using an Axiovert 40 CFL phase contrast microscope (Carl Zeiss).

Supporting information

S1 Table. Putative sterol biosynthesis genes and ORFs in *Naegleria*.
(DOCX)

S2 Table. Synergistic effect of drugs.
(DOCX)

S1 Text. Supporting information references.
(DOCX)

Acknowledgments

We thank Dean McKerrow for access to the lab instrumentation and facilities and for the critical reading of the manuscript, and Diane Thomas for excellent technical assistance and the proofreading of the manuscript.

Author Contributions

Conceptualization: Larissa M. Podust.

Data curation: Anjan Debnath, W. David Nes, Larissa M. Podust.

Formal analysis: Wenxu Zhou, Anjan Debnath, Larissa M. Podust.

Funding acquisition: Anjan Debnath, W. David Nes, Larissa M. Podust.

Investigation: Wenxu Zhou, Anjan Debnath, Gareth Jennings, Hye Jee Hahn, Boden H. Vanderloop, Minu Chaudhuri.

Methodology: Wenxu Zhou, Anjan Debnath, Gareth Jennings, Hye Jee Hahn, Minu Chaudhuri.

Project administration: Larissa M. Podust.

Resources: Anjan Debnath, W. David Nes, Larissa M. Podust.

Supervision: Larissa M. Podust.

Visualization: Gareth Jennings.

Writing – original draft: Larissa M. Podust.

Writing – review & editing: Anjan Debnath, W. David Nes, Larissa M. Podust.

References

1. Visvesvara GS. Infections with free-living amebae. *Handb Clin Neurol*. 2013; 114:153–68. <https://doi.org/10.1016/B978-0-444-53490-3.00010-8> PMID: 23829906
2. Grace E, Asbill S, Virga K. *Naegleria fowleri*: pathogenesis, diagnosis, and treatment options. *Antimicrob Agents Chemother*. 2015; 59(11):6677–81. <https://doi.org/10.1128/AAC.01293-15> PMID: 26259797

3. Chomba M, Mucheleng'anga LA, Fwoloshi S, Ngulube J, Mutengo MM. A case report: primary amoebic meningoencephalitis in a young Zambian adult. *BMC Infect Dis*. 2017; 17(1):532. <https://doi.org/10.1186/s12879-017-2638-8> PMID: 28764655
4. De Jonckheere JF. Origin and evolution of the worldwide distributed pathogenic amoeboflagellate *Naegleria fowleri*. *Infect Genet Evol*. 2011; 11(7):1520–8. <https://doi.org/10.1016/j.meegid.2011.07.023> PMID: 21843657
5. Zysset-Burri DC, Muller N, Beuret C, Heller M, Schurch N, Gottstein B, et al. Genome-wide identification of pathogenicity factors of the free-living amoeba *Naegleria fowleri*. *BMC Genomics*. 2014; 15:496. <https://doi.org/10.1186/1471-2164-15-496> PMID: 24950717
6. Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. *Int J Parasitol*. 2004; 34(9):1001–27. <https://doi.org/10.1016/j.ijpara.2004.06.004> PMID: 15313128
7. Debnath A, Tunac JB, Galindo-Gomez S, Silva-Olivares A, Shibayama M, McKerrow JH. Corifungin, a new drug lead against *Naegleria*, identified from a high-throughput screen. *Antimicrob Agents Chemother*. 2012; 56(11):5450–7. <https://doi.org/10.1128/AAC.00643-12> PMID: 22869574
8. Vargas-Zepeda J, Gomez-Alcala AV, Vasquez-Morales JA, Licea-Amaya L, De Jonckheere JF, Lares-Villa F. Successful treatment of *Naegleria fowleri* meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. *Arch Med Res*. 2005; 36(1):83–6. PMID: 15900627
9. Khanna V, Shastri B, Anusha G, Mukhopadhyay C, Khanna R. *Acanthamoeba meningoencephalitis* in immunocompetent: A case report and review of literature. *Trop Parasitol*. 2014; 4(2):115–8. <https://doi.org/10.4103/2229-5070.138540> PMID: 25250233
10. Kaminsky R. Miltefosine Zentaris. *Curr Opin Investig Drugs*. 2002; 3(4):550–4. PMID: 12090722
11. Cope JR, Conrad DA, Cohen N, Cotilla M, DaSilva A, Jackson J, et al. Use of the novel therapeutic agent miltefosine for the treatment of Primary Amebic Meningoencephalitis: report of 1 fatal and 1 surviving case. *Clin Infect Dis*. 2016; 62(6):774–6. <https://doi.org/10.1093/cid/civ1021> PMID: 26679626
12. Desmond E, Gribaldo S. Phylogenomics of sterol synthesis: insights into the origin, evolution, and diversity of a key eukaryotic feature. *Genome Biol. Evol*. 2009; 1:364–81. <https://doi.org/10.1093/gbe/evp036> PMID: 20333205
13. Sharma AI, Olson CL, Mamede JI, Gazos-Lopes F, Epting CL, Almeida IC, et al. Sterol targeting drugs reveal life cycle stage-specific differences in trypanosome lipid rafts. *Sci Rep*. 2017; 7(1):9105. <https://doi.org/10.1038/s41598-017-08770-9> PMID: 28831063
14. Simons K, Ikonen E. Functional rafts in cell membranes. *Nature*. 1997; 387(6633):569–72. <https://doi.org/10.1038/42408> PMID: 9177342
15. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. *Science*. 2010; 327(5961):46–50. <https://doi.org/10.1126/science.1174621> PMID: 20044567
16. Goldston AM, Powell RR, Temesvari LA. Sink or swim: lipid rafts in parasite pathogenesis. *Trends Parasitol*. 2012; 28(10):417–26. <https://doi.org/10.1016/j.pt.2012.07.002> PMID: 22906512
17. Xu X, Bittman R, Duportail G, Heissler D, Vilcheze C, London E. Effect of the structure of natural sterols and sphingolipids on the formation of ordered sphingolipid/sterol domains (rafts). Comparison of cholesterol to plant, fungal, and disease-associated sterols and comparison of sphingomyelin, cerebroside, and ceramide. *J Biol Chem*. 2001; 276(36):33540–6. <https://doi.org/10.1074/jbc.M104776200> PMID: 11432870
18. Nes CR, Singha UK, Liu J, Ganapathy K, Villalta F, Waterman MR, et al. Novel sterol metabolic network of *Trypanosoma brucei* procyclic and bloodstream forms. *Biochem J*. 2012; 443(1):267–77. <https://doi.org/10.1042/BJ20111849> PMID: 22176028
19. Raederstorff D, Rohmer M. Sterol biosynthesis de novo via cycloartenol by the soil amoeba *Acanthamoeba polyphaga*. *Biochem J*. 1985; 231(3):609–15. PMID: 4074326
20. Raederstorff D, Rohmer M. Sterol biosynthesis via cycloartenol and other biochemical features related to photosynthetic phyla in the amoebae *Naegleria lovaniensis* and *Naegleria gruberi*. *Eur J Biochem*. 1987; 164:427–34. PMID: 3569274
21. Raederstorff D, Rohmer M. The action of the systemic fungicides tridemorph and fenpropimorph on sterol biosynthesis by the soil amoeba *Acanthamoeba polyphaga*. *Eur J Biochem*. 1987; 164(2):421–6. PMID: 3569273
22. Debnath A, Calvet CM, Jennings G, Zhou W, Aksenov A, Luth MR, et al. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). *PLoS Negl Trop Dis*. 2017; 11(12):e0006104. <https://doi.org/10.1371/journal.pntd.0006104> PMID: 29284029
23. Nes WD. Biosynthesis of cholesterol and other sterols. *Chem Rev*. 2011; 111(10):6423–51. <https://doi.org/10.1021/cr200021m> PMID: 21902244

24. Nes WD. Enzyme mechanisms for sterol C-methylations. *Phytochemistry*. 2003; 64(1):75–95. PMID: [12946407](#)
25. Nes WD. Sterol methyl transferase: enzymology and inhibition. *Biochim Biophys Acta*. 2000; 1529(1–3):63–88. PMID: [11111078](#)
26. Xu SH, Nes WD. Biosynthesis of cholesterol in the yeast mutant erg6. *Biochem Biophys Res Commun*. 1988; 155(1):509–17. PMID: [3046617](#)
27. Millard P, Letisse F, Sokol S, Portais JC. IsoCor: correcting MS data in isotope labeling experiments. *Bioinformatics*. 2012; 28(9):1294–6. <https://doi.org/10.1093/bioinformatics/bts127> PMID: [22419781](#)
28. Wollam J, Magomedova L, Magner DB, Shen Y, Rottiers V, Motola DL, et al. The Rieske oxygenase DAF-36 functions as a cholesterol 7-desaturase in steroidogenic pathways governing longevity. *Aging Cell*. 2011; 10(5):879–84. <https://doi.org/10.1111/j.1474-9726.2011.00733.x> PMID: [21749634](#)
29. Mercer EI. Morpholine antifungals and their mode of action. *Biochem Soc Trans*. 1991; 19(3):788–93. PMID: [1783217](#)
30. Lamb DC, Warrilow AG, Rolley NJ, Parker JE, Nes WD, Smith SN, et al. Azole antifungal agents to treat the human pathogens *Acanthamoeba castellanii* and *Acanthamoeba polyphaga* through inhibition of sterol 14alpha-demethylase (CYP51). *Antimicrob Agents Chemother*. 2015; 59(8):4707–13. <https://doi.org/10.1128/AAC.00476-15> PMID: [26014948](#)
31. de Macedo-Silva ST, Visbal G, Urbina JA, de Souza W, Rodrigues JC. Potent *in vitro* antiproliferative synergism of combinations of ergosterol biosynthesis inhibitors against *Leishmania amazonensis*. *Antimicrob Agents Chemother*. 2015; 59(10):6402–18. <https://doi.org/10.1128/AAC.01150-15> PMID: [26239973](#)
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv. Enzyme Regul*. 1984; 22:27–55. PMID: [6382953](#)
33. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol Rev*. 2006; 58(3):621–81. <https://doi.org/10.1124/pr.58.3.10> PMID: [16968952](#)
34. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. *Mol Interv*. 2003; 3(2):90–105, 51. <https://doi.org/10.1124/mi.3.2.90> PMID: [14993430](#)
35. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. *NeuroRx*. 2005; 2(1):3–14. <https://doi.org/10.1602/neurorx.2.1.3> PMID: [15717053](#)
36. Maurice T, Su TP. The pharmacology of sigma-1 receptors. *Pharmacol Ther*. 2009; 124(2):195–206. <https://doi.org/10.1016/j.pharmthera.2009.07.001> PMID: [19619582](#)
37. Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. *Adv Exp Med Biol*. 2017; 964:153–61. https://doi.org/10.1007/978-3-319-50174-1_11 PMID: [28315270](#)
38. Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. *Curr Pharm Des*. 2012; 18(7):875–83. PMID: [22288409](#)
39. Lee J, Kim JH, Sohn HJ, Yang HJ, Na BK, Chwae YJ, et al. Novel cathepsin B and cathepsin B-like cysteine protease of *Naegleria fowleri* excretory-secretory proteins and their biochemical properties. *Parasitol Res*. 2014; 113(8):2765–76. <https://doi.org/10.1007/s00436-014-3936-3> PMID: [24832815](#)
40. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, et al. A high-throughput drug screen for *Entamoeba histolytica* identifies a new lead and target. *Nat Med*. 2012; 18(6):956–60. <https://doi.org/10.1038/nm.2758> PMID: [22610278](#)
41. Nes WD, Venkatramesh M. Molecular asymmetry and sterol evolution. Isopentenoids and other natural products. ACS Symposium Series. 562: American Chemical Society; 1994. p. 55–89.